Remoxy Review Shows How Opana ER Experience Changed US FDA Thinking On New Opioid Formulations

 
• By Sue Sutter
American Football Goal Posts
What the US FDA sees as new and emerging methods of manipulation to defeat abuse-deterrent formulations, Pain Therapeutics sees as moving the goalposts for regulatory approval.

More from US FDA Performance Tracker

More from Regulatory Trackers